Cortavance is a cutaneous hydrocortisone spray for dogs and cats. The lipophilic properties of the product help in rapid skin penetration and also aids long standing action.
- Composition: HYDROCORTISONE
- Class: Topical Corticosteroid
Indications/Uses
- Flea Allergy Dermatitis
- Hypersensitivity reactions
Directions for use:
- Apply on the affected areas twice a day or as directed by the veterinarian.
- Care should be taken to avoid licking.
Suitable for Dogs and Cats
Disclosure:
A licensed vendor partner will deliver this medicine to you. Once the pharmacy accepts your order, the details of the pharmacy will be shared with you. Acceptance of your order is based on the validity of your doctor's prescription and the availability of the medicine.
Hydrocortisone Aceponate 0.584 mg/ml Cutaneous Spray Solution
Cortavance®
Each mi contains
Hydrocortisone aceponate..................... .84 mg .q.S.
• INDICATIONS
For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
• CONTRAINDICATIONS
Do not use on cutaneous ulcers.
• ADVERSE REACTIONS
Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases
The frequency of adverse reactions is defined using the following convention : A
- Very common (more than 1 in 10 animals treated displaying adverse reactions) a
- Common (more than 1 but less than 10 animals in 100 animals treated)
- Uncommon (more than 1, but less than 10 animals in 1,000 animals treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals treated).
- Very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
• TARGET SPECIES
Dogs
• DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Cutaneous use. Before administration, screw the pump-spray on the bottle. The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated. The recommended dosage is 1.52 ug of hydrocortisone aceponate/cm? of affected skin per day:
This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm. Repeat the treatment daily for 7 consecutive days.
Care should be taken to avoid spraying into the eyes of the animal. Presented as a volatile spray, this veterinary medicinal product does not require any massage.
In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of cola ase auo the product to the risk-benefit assessment.
If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.
• ADVICE ON CORRECT ADMINISTRATION
Spray preferably in a well-ventilated area.
Flammable.
Do not spray on a naked flame or any incandescent material. Do not smoke while handling the product.
• WITHDRAWAL PERIOD
Not applicable.
• SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children.
Store below 30°C.
• SPECIAL WARNING(S)
Special precautions for use in animals
In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.
In the absence of specific information, the use in animals suffering from Cushing's syndrome shall be based on the risk-benefit assessment.
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.
In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level was observed.
The total body surface treated should not exceed a surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs. Otherwise, use only according to the risk-benefit assessment and subject the dog to regular clinical evaluations.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Use only according to the risk-benefit assessment by the responsible veterinarian.
Special precautions are to be taken by the person administering the veterinary medicinal product to animals In case of accidental skin contact, it is recommended to wash thoroughly with water. Wash hands after use.
Avoid contact with eyes. In case of accidental eye contact, rinse with abundant quantities of water. In case of eye irritation, seek medical advice.
In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to the physician.
In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.
The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.
• OTHER INFORMATION
Hydrocortisone aceponate administered topically accumulates and is metabolized in the skin, as suggested by radioactivity distribution studies and pharmacokinetic data. This results in minimal amounts to reach the bloodstream. This particularity will increase the ratio between the desired local anti-inflammatory effect on the skin and the undesirable systemic effects.
Hydrocortisone aceponate applications on the skin lesions provide rapid reduction of skin redness, irritation, and scratching while minimizing the general effects.
After topical application on the skin at the recommended therapeutic dosage and twice the recommended duration of treatment and at up to a body surface corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs, no systemic effects are observed.
Tolerance studies using 3 and 5 times the recommended dosage for twice the recommended duration of treatment resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.
• PACK PRESENTATION
Box containing a bottle of 76ml spray solution.
FE98779/03
2ИОІТАЗІСИІАЯТИО В
• SHELF LIFE
24 months from the date of manufacture
Use within 6 months after first opening of the container.
Manufactured by:
VIRBAC S.A.
FRANCE
Imported by:
Virbac Animal Health India Pvt, Ltd.,
Shri Arihant Annexe, Gala No. 1 to 4, Shri Arihant Comm. Comp., Kalher Village, Dist. Thane Zone 5, Taluka - Bhiwandi, Thane - 421302
50 190 - 01 JM916VIUDS D936913
Marketed by:
Virbac Animal Health India Pvt. Ltd.,
604, 6th Floor, Western Edge-I, Magathane, Western Express Highway, Borivali (East), Mumbai - 400 066 ® Owner of Registered Trademark Virbac S.A.
